Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), now classified as coronavirus disease 2019 (COVID-19), was first identified in December 2019 in Wuhan, China, and has now spread to all continents except Antarctica. It was assigned pandemic status by the World Health Organization in March 2020. An estimated 80% of cases have been mild or asymptomatic, while the remaining 20% of cases develop severe and critical presentations that require hospitalization and are associated with a myriad of complications. Although COVID-19 is a respiratory disease, clinical reports suggest that severe cases reflect a confluence of vascular dysfunction, thrombosis, and dysregulated inflammation. The most common complications include pneumonia, respiratory failure and acute respiratory distress syndrome (ARDS), sepsis and septic shock, cardiomyopathy, acute kidney injury (AKI), and pulmonary thromboembolism. Other complications include acute stroke, arrhythmias, acute cardiac injury, and dermatologic manifestations.
Updated October 11, 2020
Table of Contents
Share this page:
Risk Factors and Disease Progression
Anyone can be infected with and develop symptoms of COVID-19. However, certain population groups are at higher risk of progressing to severe or critical infection, complications, or death. Risk factors (from highest to lowest risk) include the following:
- Age > 65 years
- The mortality rate for patients < 65 is < 3%. However, this rises to 3%–11% for individuals aged 65–84 and 10%–27% for individuals ≥ 85 years of age.
- Chronic diseases
- Chronic lung disease
- Cardiovascular disease
- Severe obesity (body mass index > 40)
- Diabetes mellitus, chronic kidney disease requiring dialysis, cerebrovascular disease, and liver disease
- Higher risk of severe illness, but same risk of infection as non-pregnant patients
Symptoms appear an average of 5 days after infection. Initial presentation can vary greatly, although COVID-19 usually presents as a respiratory syndrome. Common signs and symptoms include fever, fatigue, dry cough, anosmia (loss of smell), dysgeusia (loss of taste), anorexia, congestion, headache, myalgia, and gastrointestinal upset.
Clinical deterioration and/or the development of complications mostly occurs in the second week of illness and is usually marked by the appearance and worsening of dyspnea.
Although COVID-19 is a respiratory disease, emerging data and clinical reports increasingly suggest that severe cases reflect a confluence of vascular dysfunction, thrombosis, and dysregulated inflammation. The development of complications and organ damage may be due not only to direct organ damage caused by the viral infection and local inflammation but also by indirect pathogenic mechanisms, including widespread endothelial damage (endothelialitis) with microangiopathy involving the vascular beds of the lungs, heart, kidneys, liver, and intestines; thrombosis and disseminated intravascular coagulation; an atypical inflammatory response; and autoimmune phenomena such as Guillain-Barré syndrome and pediatric inflammatory multisystem syndrome, an inflammatory state with clinical features similar to those of Kawasaki disease and toxic shock syndrome.
The most common complications include pneumonia, respiratory failure and acute respiratory distress syndrome (ARDS), sepsis and septic shock, cardiomyopathy, acute kidney injury (AKI), and pulmonary thromboembolism.
Other complications include:
- Acute stroke
- Cardiac arrhythmias
- Acute cardiac injury
- Various dermatologic manifestations:
- Papulovesicular eruption involving mainly the trunk associated with active viremia
- Chilblain-type lesions of the fingers and toes (“COVID toes”) which last 3 or 4 weeks, most likely due to an immune response
Survivors of severe infections are likely to be at high risk for pulmonary fibrosis, and therefore antifibrotic therapies may be beneficial both in the acute phase of the illness and in preventing long-term complications.
- Not a complication, but the most frequent manifestation of severe infection
- Characterized in most cases by high fever, dry or productive cough, chest pain, and moderate to severe dyspnea
- Dyspnea develops approximately 5 days after the onset of symptoms, and hospital admission usually occurs after 7 days of symptoms.
- Laboratory findings: lymphocytopenia and elevated C-reactive protein
- Bilateral ground-glass opacities that can progress to solid white consolidation
- “Crazy paving” pattern (ground-glass opacities with superimposed interlobular and intralobular septal thickening)
- Lesions have a bilateral, peripheral, and lower lung zone distribution.
- Includes hospital-acquired pneumonia and ventilator-associated pneumonia
- Much less common than viral pneumonia (approximately 10% of critical cases)
- If bacterial pneumonia is suspected, the use of broad-spectrum empiric antimicrobial therapy is recommended.
- Performing pulmonary diagnostic procedures, such as bronchoscopy or other types of airway sampling, is not advised.
- Laboratory findings: ↑ procalcitonin
- Imaging: findings of viral pneumonia plus lobar consolidation, air bronchograms, and pleural effusion
Acute Respiratory Failure and ARDS
ARDS is characterized by the following:
- Acute hypoxemic respiratory failure
- Presents within 1 week of worsening respiratory symptoms
- Bilateral opacities on chest X-ray, computed tomography, or ultrasound that are not fully explained by effusions, lobar or lung collapse, or nodules
- Cardiac failure ruled out
The histologic manifestation of ARDS is diffuse alveolar damage, which may occur either due to an injury to the airway (alveolar component) or the endothelium (hematologic component) of the alveolar membrane. Interstitial pneumonitis is typically seen in the early stages, and ARDS commonly follows in severe cases. The SARS-CoV-2 virus is unusual because it attacks cells with angiotensin-converting enzyme 2 (ACE2) receptors on both sides of the alveolar membrane and thereby provokes an intense inflammatory response, with subsequent accumulation of intra-alveolar fluid and formation of hyaline membranes.
The vascular pathology of ARDS in COVID-19 patients is dramatic, as seen in one autopsy study which found that the lungs of a patient with COVID-19 had 9 times as many clots as those who died of the H1N1 flu. Pathological studies have shown that the main pathological features in the lungs of patients who died from COVID-19 include extensive impairment of type I alveolar epithelial cells and atypical hyperplasia of type II alveolar cells. ACE2 has a direct protective role in alveolar epithelial cells and its loss by viral infection leads to alveolar cell damage and an increase in angiotensin II levels, which triggers the IL-6 amplifier inflammatory pathway and release of cytokines similar to a cytokine storm. Reports also show the formation of hyaline membranes, focal hemorrhages, exudation and pulmonary edema, pulmonary consolidation, and the direct binding of macrophages to the S protein of SARS-CoV-2.
Resolution of the injury is impeded by a marked degree of epithelial necrosis and inflammatory damage and probably accounts for the reportedly more compliant ARDS lungs and severe (and often “silent”) hypoxemia seen in the early stages of COVID-19 cases compared with the classic ARDS lung. The virus also gains wide access to the systemic circulation, leading to the infection of endothelial cells throughout the body and the infection of many other organs with ACE2 receptors. The virus has also been found in T lymphocytes, macrophages, and monocyte-derived dendritic cells. Direct viral destruction of lymphocytes could contribute to the observed lymphopenia in patients. Viral infection in immune cells, such as monocytes and macrophages, can result in aberrant cytokine production, even if viral infection is not productive. Extension of the pathologic process in the lung results in progressive hypoxemia and respiratory failure.
Acute respiratory failure is the leading cause of mortality in patients with COVID-19.
Respiratory failure from ARDS is the most common finding in critical COVID-19 cases.
- Develops in 15%–30% of total cases and 60%–80% of those requiring intensive care unit (ICU) care
- Progresses quickly after the onset of dyspnea, with a median time to intubation of 8.5 days after symptom onset
- Mortality rate of 25%–50% (higher in patients who receive mechanical ventilation)
- Respiratory rate and oxygen saturation (SpO2) are important parameters for patient assessment and allow for early recognition of ARDS. The following conditions indicate severe disease:
- Respiratory rate ≥ 30 bpm
- SpO2 ≤ 92%
- PaO2/FiO2 ≤ 300 mmHg
- Imaging and laboratory findings are similar to those in COVID-19 pneumonia.
Breathing support is very important in treating any COVID-19 respiratory complication. Key elements include oxygen therapy by nasal cannula, high-flow nasal oxygen, prone mechanical ventilation, and extracorporeal membrane oxygenation for rescue. Most guidelines recommend early intubation and mechanical ventilation. Survivors of severe infections are likely to be at high risk for pulmonary fibrosis, and antifibrotic therapies may therefore be beneficial both in the acute phase of the illness and in preventing long-term complications.
Non-invasive ventilation (CPAP and BiPAP) are aerosol-generating procedures and should only be used when appropriate measures of infection prevention and control are in place.
Sepsis and Septic Shock
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock is the presence of sepsis with circulatory, cellular, and metabolic abnormalities that significantly increase mortality. The two main characteristics of septic shock are persisting hypotension requiring vasopressors to maintain MAP ≥ 65 mm Hg and a serum lactate level > 2 mmol/L (18 mg/dL) despite adequate volume resuscitation. Organ dysfunction is assessed via the Sequential Organ Failure Assessment (SOFA) score (see table below).
Sequential Organ Failure Assessment score (SOFA score)
|Organ or System||Parameter||0||+1||+2||+3||+4|
|Repiration System||PaO2/FiO2 (mmHg)||≥ 400||300–399||200–299||100–199 + mechanically ventilated||< 100 + mechanically ventilated|
|Nervous system||Glasgow Coma Scale||15||13–14||10–12||6–9||< 6|
|Cardiovascular System||Mean arterial pressure (MAP) OR need for vasopressors||MAP ≥ 70 mmHG||MAP < 70 mmHG||Dopamine|
≤ 5 μg/kg/min,
or dobutamine (any dose)
> 5 μg/kg/min,
≤ 0.1 μg/kg/min, or norepinephrine ≤ 0.1 μg/kg/min
> 15 μg/kg/min,
> 0.1 μg/kg/min, or
norepinephrine > 0.1 μg/kg/min
|Liver||Bilirubin (mg/dL)||< 1.2||1.2–1.9||2–5.9||6–11.9||> 12|
|Coagulation||Platelets x 103/μl||≥ 150||100–149||50–99||20–49||< 20|
|Kidney||Creatinine (mg/dL) or urine output||< 1.2||1.2–1.9||2–3.4||3.5–4.9|
< 500 mL/day
< 200 mL/day
|Repiration system PaO2/FiO2 (mmHg)||0||≥ 400|
|+3||100–199 + mechanically ventilated|
|+4||< 100 + mechanically ventilated|
|Nervous system Glascow Coma Scale||0||15|
|Cardiovascular system Mean arterial pressure (MAP) OR need for vasopressors||0||MAP ≥ 70 mmHg|
|+1||MAP < 70 mmHg|
|+2||Dopamine ≤ 5 µg/kg/min or dobutamine (any dose)|
|+3||Dopamine > 5 µg/kg/min or epinephrine ≤ 0.1 µg/kg/min or norepinephrine ≤ 0.1 µg/kg/min|
|+4||Dopamine > 15 µg/kg/min or epinephrine > 0.1 µg/kg/min or norepinephrine > 0.1 μg/kg/min|
|Liver Bilirubin (mg/dL)||0||< 1.2|
|Coagulation Platelets × 103/µl||0||≥ 150|
|Kidneys Creatinine (mg/dL) or urine output||0||< 1.2|
|+3||3.4–4.9 or < 500 mL/day|
|+4||> 5 or < 200 mL/day|
In COVID-19 patients, sepsis and septic shock are thought to result from the cytokine storm that develops in addition to organ damage caused by direct ACE2 attachment and/or progressive hypoxemia.
- Septic shock is reported in 4%–8% of cases (less common than pneumonia or ARDS)
- Can quickly deteriorate to multi-organ failure and death
- Aside from the signs and symptoms normally associated with COVID-19, sepsis and septic shock can present with:
- Persistently high fever, chills, and diaphoresis OR hypothermia
- Altered mental status in cases of central nervous system impairment
- Hypotension in cases of hemodynamic failure
- Petechiae and purpura in cases of coagulopathy
- Jaundice in cases of liver failure
- Oliguria or anuria in cases of renal failure
For the latest step-by-step management guidelines, see the “WHO interim guidance on clinical management of COVID-19” and the “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.”
Patients with COVID-19 commonly present with signs of cardiac disease. This seems to be a late complication, at times developing after the respiratory illness improves. The range of cardiac complications is extensive and includes myocarditis, acute myocardial injury, arrhythmias, heart failure, and sudden death.
The exact cause of COVID-19–related cardiac complications is still under investigation and can vary from case to case. Possible etiologies include direct myocardial and pericardial damage due to ACE2 attachment, ischemic or stress-induced damage due to persistent hypoxemia, inflammation due to cytokine storm, and sequelae of organ dysfunction induced by septic shock.
Cardiac complications are also more frequent in severe and critical COVID-19 cases as these patients are usually older, have preexisting cardiovascular diseases, and take ACE inhibitors or angiotensin II receptor blockers (which increase ACE2 expression).
The exact incidence and mortality rate of COVID-19-related cardiac complications are unknown. Current rates only reflect the results of studies with small sample sizes or specific patient groups.
- Myocarditis and pericardial dysfunction occur in approximately 20% of patients.
- Acute myocardial injury has been reported in 7%–28% of patients.
- Arrhythmias have been reported in 15%–20% of patients.
- Myocardial infarction and heart failure have been reported in 8% and 2% of patients, respectively.
- 40% of deaths from COVID-19 are related to cardiovascular complications (up to 7% are attributable to myocarditis alone).
- Cardiac disease in severe and critical COVID-19 cases usually requires admission to the ICU and have a poor prognosis and a higher rate of in-hospital mortality.
If a cardiac complication is suspected, additional laboratory tests should be performed. Cardiac enzymes (troponin and NT-proBNP) are usually elevated, but negative troponin cannot exclude cardiac disease. Electrocardiogram (ECG) abnormalities vary greatly and can include ST elevation, PR depression, new-onset bundle branch block, QT prolongation, pseudoinfarct pattern, premature beats, and bradyarrhythmia with atrioventricular block.
Many patients with COVID-19 develop abnormal coagulation profiles along with venous and arterial thrombosis of the large and small vessels. Thromboembolic complications, including pulmonary embolism and acute stroke, have also been reported. Up to 40% of deaths from COVID-19 are related to cardiovascular complications. These findings suggest a hypercoagulable state called COVID-19–associated coagulopathy (CAC).
Pulmonary embolism and deep vein thrombosis have been reported in 20%–30% of severe cases in the ICU.
The pathogenesis of CAC is still unclear but may be due to hypoxia and systemic inflammation secondary to COVID-19, which leads to the release of proinflammatory cytokines and activation of the coagulation pathway. It is also theorized that the SARS-CoV-2 virus can cause direct vascular damage by targeting and spreading through endothelial cells in the blood vessels. Endothelial injury and dysfunction would not only hinder the physiological inhibition of clot formation but also provide the first factor of Virchow’s triad.
The three factors of thrombosis, or Virchow’s triad, can be seen in cases of severe COVID-19 infection:
- Endothelial injury through cytokine storm and direct endothelial invasion by SARS-CoV-2
- Stasis due to immobilization during hospitalization, especially in the ICU
- Hypercoagulable state through a rise in circulating prothrombotic factors
Vascular damage may explain why individuals with chronic conditions (e.g., hypertension, diabetes, or cardiovascular disease) are at a higher risk for severe complications from what is presumed to be a simple respiratory illness. It could also explain why ventilation alone has not been an effective treatment for many patients, as well as why such a vast variety of organs can be affected by the virus.
Endothelial damage and coagulopathy may be behind the significant organ damage that can occur in some cases of COVID-19.
Laboratory abnormalities commonly observed in patients with COVID-19–associated coagulopathy include thrombocytopenia, increased D-dimer and fibrinogen levels, and prolonged prothrombin time. Elevated D-dimer levels, high ferritin levels, and low platelet counts are strongly associated with a greater risk of death.
Other Types of Organ Damage
Abnormal liver function has been reported in approximately 15% of COVID-19 patients. Cases with acute liver injury and liver failure have presented with high levels of aspartate aminotransferase, alanine aminotransferase, and total bilirubin, and lower levels of serum albumin. Liver dysfunction is associated with a significant increase in the severity of COVID-19 infection.
Acute kidney injury has been reported in 3%–36% of hospitalized patients with COVID-19. Approximately 15% of hospitalized patients with critical infection require renal replacement therapy. Kidney dysfunction is associated with a higher risk of mortality. The pathogenesis is still unknown, although it is hypothesized to be due to cytokine storm, hypoxemic hemodynamic changes, and/or thrombotic events.
AKI can present with hematuria or proteinuria and altered kidney injury markers, urine microscopy, quantified urine protein, urine output, and urine electrolytes. Risk factors include age ≥ 65 years, black ethnicity, history of AKI, chronic kidney disease, cardiovascular disease, hypertension, heart failure, liver disease, and diabetes.
Neurologic symptoms and complications have also been reported in up to 55% of patients with critical COVID-19 infections. These include altered mental status, delirium, encephalopathy, acute cerebrovascular disease or stroke, ataxia, seizures, corticospinal tract signs, meningitis, encephalitis, and Guillain-Barré syndrome. Using diffusor tensor and 3D high-resolution MRI, microstructural changes have been reported in the brain of COVID-19 patients. Significantly higher bilateral gray matter volumes were seen in areas of the brain that correlate with the COVID-19 symptoms of smell loss, memory loss, and LDH elevation. This suggests that there may be long-term neurological consequences of SARS-CoV-2-infection.
Dermatologic complications, including rashes and other lesions, have been identified in 5%–20% of patients in recent reports. These lesions include maculopapular rashes, urticarial and vesicular lesions, petechiae/purpura, chilblains, livedo reticularis, and distal ischemia or necrosis. The pathogenesis varies depending on the lesion and includes direct viral infection, immunologic reaction, and thromboembolism.
Ocular complications (acute conjunctivitis) have been reported in 0.9% of infected patients.
COVID-19–Associated Complications in Children
The clinical presentation and severity of cases of COVID-19 in patients < 18 years old is different from that of adults. Children have a lower risk of developing severe or critical infections, and complications appear to be milder.
- Approximately 55% of cases are asymptomatic or mild
- 40% of cases are moderate (pneumonia and/or abnormal chest imaging)
- 5% of cases are severe (dyspnea and hypoxia, requiring oxygen therapy)
- < 1% of cases are critical (ARDS, respiratory failure, shock, or multi-organ failure requiring ICU transfer)
Pediatric inflammatory multisystem syndrome is a newly discovered complication occurring in pediatric patients. The case definition by the Royal College of Paediatrics and Child Health includes the following criteria:
- A child presenting with persistent fever (≥ 4 days), inflammation (neutrophilia, elevated C-reactive protein, and lymphopenia) and evidence of single- or multi-organ dysfunction (shock or cardiac, respiratory, renal, gastrointestinal, or neurological disorder)
- This may include children fulfilling full or partial criteria for Kawasaki disease.
- Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, and infections associated with myocarditis (enterovirus)
- SARS-CoV-2 PCR testing may be positive or negative.
Respiratory symptoms are only present in half of these patients. Abdominal symptoms such as abdominal pain, vomiting, or diarrhea are also common.
- Tay, M.Z., Poh, C.M., Rénia, L. et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20, 363–374 (2020). Published Apr 28, 2020. https://doi.org/10.1038/s41577-020-0311-8
- South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Integrative Cardiovascular Physiology and Pathophysiology. Published Apr 13, 2020. https://doi.org/10.1152/ajpheart.00217.2020
- Joly, B.S., Siguret, V. & Veyradier, A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med (2020). https://doi.org/10.1007/s00134-020-06088-1
- Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54-67. doi:10.1007/s11239-020-02134-3
- Lemke, G., Silverman, G.J. Blood clots and TAM receptor signalling in COVID-19 pathogenesis. Nat Rev Immunol (2020). https://doi.org/10.1038/s41577-020-0354-x
- von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet. Published: June 04, 2020. DOI:https://doi.org/10.1016/S0140-6736(20)31282-4
- Zhang, H., Penninger, J.M., Li, Y. et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 46, 586–590 (2020). https://doi.org/10.1007/s00134-020-05985-9
- Li, M., Li, L., Zhang, Y. et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 9, 45 (2020). https://doi.org/10.1186/s40249-020-00662-x
- Soy, M., Keser, G., Atagündüz, P. et al. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 39, 2085–2094 (2020). https://doi.org/10.1007/s10067-020-05190-5
- Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427. doi:10.1016/j.clim.2020.108427
- Ng SC, Tilg H. COVID-19 and the gastrointestinal tract: more than meets the eye. Gut. First published as 10.1136/gutjnl-2020-321195 on 9 April 2020. https://gut.bmj.com/content/gutjnl/69/6/973.full.pdf
- Xu, Zhe & Shi, Lei & Wang, Y. & Zhang, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. Published Feb 17, 2020. 8. 10.1016/S2213-2600(20)30076-X. https://www.researchgate.net/publication/339340520_Pathological_findings_of_COVID-19_associated_with_acute_respiratory_distress_syndrome
- Leisman, D.E., Deutschman, C.S. & Legrand, M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med 46, 1105–1108 (2020). https://doi.org/10.1007/s00134-020-06059-6
- Samavati L, Uhal BD. ACE2, Much More Than Just a Receptor for SARS-COV-2. Front. Cell. Infect. Microbiol., 05 June 2020 | https://doi.org/10.3389/fcimb.2020.00317
- Toshio Hirano et al. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome, Immunity (2020). DOI: 10.1016/j.immuni.2020.04.003
- Gottlieb M, Long B. Dermatologic manifestations and complications of COVID-19 [published online ahead of print, 2020 Jun 6]. Am J Emerg Med. 2020;doi:10.1016/j.ajem.2020.06.011
- Lipsker D. Paraviral eruptions in the era of COVID-19. Do some skin manifestations point to a natural resistance to SARS-CoV-2? Clinics in Dermatology. Published June 13, 2020. https://doi.org/10.1016/j.clindermatol.2020.06.005
- Ackermann M, Stijn SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. Published May 21, 2020. DOI: 10.1056/NEJMoa2015432
- China Medical Treatment Expert Group for Covid-19, Clinical Characteristics of Coronavirus Disease 2019 in China, DOI: 10.1056/NEJMoa2002032
- Masetti C, Generali E, Colapietro F, et al. High mortality in COVID‐19 patients with mild respiratory disease. European J Clinical Investigation. First published:14 June 2020. https://doi.org/10.1111/eci.13314. https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13314
- Husain AN. The Lung. In Chapter 15 of Robbins and Cotran, Pathologic Basis of Disease, 9th ed. 2015. Elsevier.
- Levitan R. The Infection That’s Silently Killing Coronavirus Patients. New York Times, Apr 23, 2020.